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Abstract
The c-KIT proto-oncogene has been implicated in the
pathogenesis of several neoplastic diseases, including
gastrointestinal stromal tumors and mastocytosis in
humans, and mast cell tumors (MCTs) in canines. Cuta-
neous MCTs are common neoplasms in dogs and have
a variable biologic behavior. The goal of this study
was to define the prognostic significance of c-KITmuta-
tions identified in canine MCTs and the associations
between c-KIT mutations, KIT localization, and KIT ex-
pression levels. Microdissection and polymerase chain
reaction were performed on 60 MCTs to identify c-KIT
mutations. Anti-KIT antibodies were used for immuno-
histochemical evaluation of KIT localization. Forty-two
MCTs were included in a tissue microarray, and KIT
expression was quantified using immunofluorescence.
Canine MCTs with c-KIT mutations were significantly
associated with an increased incidence of recurrent
disease and death. c-KIT mutations were also signifi-
cantly associated with aberrant protein localization;
however, the level of KIT expression did not correlate
with either c-KIT mutations or changes in protein lo-
calization. Considering the high prevalence of canine
MCTs and the central role of c-KIT in the tumorigenesis
of certain tumors, canine MCTs are an excellent model
for characterizing the role of c-KIT in neoplastic
diseases and is a potential target for novel therapeutic
agents in clinical trials.
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Introduction
The c-KIT proto-oncogene encodes the receptor tyrosine
kinase KIT, which consists of an extracellular ligand bind-
ing domain composed of five immunoglobulin-like loops, a
transmembrane domain, a negative regulatory juxtamem-
brane domain, and a split cytoplasmic kinase domain [1–3].
The ligand for KIT is stem cell factor, which is also known as
steel factor, KIT ligand, or mast cell growth factor [4–7]. The
receptor tyrosine kinase KIT is expressed by multiple cell types,
including hematopoietic progenitor cells, germ cells, interstitial
cells of Cajal, melanocytes, and mast cells, where it has been
associated with cell survival, proliferation, and differentiation
[8–14]. In addition to these functions, in mast cells, KIT has
been shown to be important for fibronectin adhesion, chemo-
taxis, and degranulation [5,15–19].
Recently, c-KIT has been implicated in the pathogenesis
of multiple human neoplastic diseases. c-KIT mutations, which
lead to a constitutively activated KIT product in the absence
of ligand, have been identified in the juxtamembrane domain
of gastrointestinal stromal tumors in humans [20] and in the
kinase domain at codon 816 of human mastocytosis patients
[21–23]. Additionally, aberrant KIT expression is increasingly
being identified in multiple neoplasms, including small cell lung
cancer, prostate cancer, and acute myeloblastic leukemia
[24–29]. The significance of this aberrant expression has been
determined for some of these cancers, such as small cell lung
cancer, where autocrine and paracrine signaling loops have
been identified [24,26], and in prostate cancer, where trun-
cated isoforms of KIT that signal through phospholipase C-g1
have been characterized [27,30]. However, for several other
cancers, the significance of this aberrant expression has not
been elucidated.
Activating c-KIT mutations [31–34] and aberrant KIT ex-
pression has also been described in canine cutaneous mast
cell tumors (MCTs) [35–39], therefore implicating c-KIT in their
pathogenesis. Unlike mastocytosis in humans, which is a rather
Abbreviations: MCT, mast cell tumor; LCM, laser capture microdissection; ITD, internal
tandem duplication; HR, hazard ratio; OR, odds ratio
Address all correspondence to: Matti Kiupel, Diagnostic Center for Population and Animal
Health, 4125 Beaumont Road, Room 152A, Lansing, MI 48910. E-mail: kiupel@dcpah.msu.edu
1Funding for this study was provided, in part, by the Companion Animal Fund of the College of
Veterinary Medicine, Michigan State University. J.D.W. was funded by a National Institutes of
Health T-32 postdoctoral training grant (no. RR17189).
Received 16 September 2005; Revised 10 November 2005; Accepted 11 November 2005.
Copyright D 2006 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05622
Neoplasia . Vol. 8, No. 2, February 2006, pp. 104 –111 104
www.neoplasia.com
RESEARCH ARTICLE
rare condition and usually has a positive prognosis [40–42],
canine cutaneous MCTs are one of the most common neo-
plastic diseases in dogs (accounting for 7–21% of all cuta-
neous neoplasms) [43–46] and have an extremely variable
biologic behavior ranging from a benign mass to a fatal me-
tastatic disease [34,47,48]. Canine cutaneous MCTs com-
monly present as a solitary neoplastic mass in the skin and/or
subcutaneous tissue of older dogs, with mean age of onset of
approximately 9 years of age. There is no reported sex pre-
dilection [49,50]. All breeds of dogs are affected by MCTs,
but several breeds, such as the boxer, Boston terrier, bull-
dog, Weimaraner, and Labrador retriever, have been sug-
gested to have an increased incidence of the disease
[45,51]. Prognostic and therapeutic determinations for ca-
nine cutaneous MCTs are commonly based on histologic
grading. Several histologic grading systems have been
developed for the evaluation of canine cutaneous MCTs
[47,48]. The most commonly used system is that proposed
by Patnaik et al. [48], which defines grade 1 MCTs as being
well-differentiated tumors with good prognosis, grade 3
MCTs as being poorly differentiated tumors with poor prog-
nosis, and grade 2 MCTs as being of intermediate differ-
entiation with intermediate prognosis.
c-KIT mutations have been identified in the juxtamem-
brane domain, primarily in exon 11, of canine MCTs and
consist of internal tandem duplications (ITDs) and deletions
[31–34,52–55]. ITD c-KIT mutations were identified in 9%
of canineMCTs in one study that looked at themutation status
of 88 randomly selected MCTs [33], but these mutations
may occur in as many as 30% to 50% of all intermediate- to
high-grade MCTs [53]. All, except for one, of the previously
described ITDs are in-frame duplications that range from
approximately 39 to 69 bp in size [31–34,53–55], and all of
the mutations that have been characterized thus far pro-
duce a constitutively activated form of KIT in the absence of
ligand [31,32,54]. Previous work by our laboratory has
shown that c-KIT mutations are significantly associated with
histologically higher-grade canine MCTs [33]. Recently, our
laboratory has also shown that increased cytoplasmic locali-
zation of KIT in canine MCTs is significantly associated with
a decreased survival duration and disease-free interval as
compared to MCTs with perimembrane KIT localization [39].
The goal of this study was to define the prognostic sig-
nificance of c-KIT mutations, and the associations between
c-KIT mutations, KIT localization, and KIT expression levels
in canine MCTs. Mutations in c-KIT ’s juxtamembrane do-
main were identified in 15% of the MCTs examined, using
laser capture microdissection (LCM) and polymerase chain
reaction (PCR) amplification. This is the first study to show
that c-KIT mutations in canine MCTs are significantly asso-
ciated with decreased disease-free and overall survival, and
that a significant relationship between KIT protein localiza-
tion and the presence of c-KIT mutations exists in canine
MCTs. These data clearly implicate an important role of c-KIT
in the progression of canine cutaneous MCTs. Considering
the high prevalence of MCTs in dogs and the central role
c-KIT appears to play in the tumorigenesis of many canine
MCTs, canine cutaneous MCTs provide an excellent spon-
taneous in vivo model for studying the molecular biology of
c-KIT in human and animal neoplastic diseases. Further-
more, canine cutaneous MCTs are an excellent model for
the treatment of cancers that are driven by c-KIT and can be
used in clinical trials for testing chemotherapeutics aimed at
targeting the c-KIT proto-oncogene.
Materials and Methods
Case Selection, Tissue Samples, and Survival Data
Sixty canine cutaneous MCTs from 60 different dogs
submitted to the Michigan State University’s Diagnostic
Center for Population and Animal Health between 1998 and
2001 were included in this study. Cases were included in this
study solely based on the meeting of all inclusion criteria.
Inclusion criteria for this study were as follows: 1) all cases
were previously diagnosed as canine cutaneous MCT (the
diagnosis of canine cutaneous MCTand the histologic grade
of each tumor were confirmed by a veterinary pathologist);
2) all cases were treated with surgical excision as the only
primary treatment modality (i.e., no chemotherapy or radia-
tion therapy was used); 3) complete follow-up data from the
referring veterinarian were available; and 4) adequate for-
malin-fixed paraffin-embedded tissues for DNA extraction
and immunohistochemistry were available. Complete follow-
up data for each case included age, sex, breed, weight,
number of masses, location of mass, time before excision,
medication at the time of surgery, diagnostic tests per-
formed, recurrence, tumor margins, metastasis, survival
time, and cause of death. Histologic grading of canine MCTs
was performed in conjunction with a multi-institutional review
of the current histologic grading system for canine cutaneous
MCTs, in which 31 pathologists participated in the histologic
grading of 95 canine MCTs [56]. Histologic grades represent
a consensus of those results.
LCM and DNA Extraction
LCM was used to isolate neoplastic mast cells for DNA
extraction and subsequent PCR amplification of c-KIT exon
11 and intron 11 to identify ITD c-KITmutations. Five- to 7-mm
sections of each formalin-fixed paraffin-embedded MCT
were dehydrated and stained with hematoxylin for LCM. A
total of 2000 to 4000 neoplastic mast cells was extracted from
each tumor sample using the Pixcell LCM system with Macro
LCM caps (Arcturus, Mountain View, CA) (Figure 1). Ex-
tracted cells that adhered to the Macro LCM caps were incu-
bated overnight in 50 ml of DNA extraction buffer (10 mM Tris,
pH 8.0, 1 mM EDTA, and 1% Tween) and 1.5 ml of 15 mg/ml
Proteinase K (Roche, Indianapolis, IN) at 37jC. Samples
were centrifuged at 4000 rpm for 5minutes, and Proteinase K
was inactivated by heating at 95jC for 8 minutes.
PCR Amplification of c-KIT Exon 11 and Intron 11
PCR amplification was performed using a previously de-
scribed primer pair that flanks exon 11 and the 5V end of intron
11 [55], which includes the previously described ITD region of
the c-KIT proto-oncogene in canine MCTs [31–34,53–55].
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PCRs were prepared in a 25-ml total reaction volume, with
5 ml of LCM-extracted DNA, 5 pmol of each primer, 0.5 U of
Taq polymerase (Invitrogen, Carlsbad, CA), and final con-
centrations of 80 mM deoxynucleoside triphosphate, 2 mM
MgCl2, 20 mM Tris–HCl, and 50 ml of KCl. Cycling conditions
were as follows: 94jC for 4 minutes; 35 to 45 cycles at 94jC
for 1 minute, 55jC for 1 minute, and 72jC for 1 minute; 72jC
for 5 minutes. Amplified products and ITD mutations were
visualized by agarose gel electrophoresis on a 2% agarose
gel after ethidium bromide staining (Figure 2).
DNA Sequencing
Mutant c-KIT alleles were identified by agarose gel elec-
trophoresis, and DNA fragments were excised for DNA purifi-
cation. DNA was purified using the Qiaex II gel purification kit
(Qiagen, Valencia, CA) according to the manufacturer’s
protocol. DNA fragments were subcloned into Topo vectors
using the Topo cloning kit (Invitrogen) and were subse-
quently chemically transformed into competent Escherichia
coli cells according to the manufacturer’s protocol. c-KIT
clones were sequenced either through an automated se-
quencing technique using fluorescently labeled dideoxynu-
cleotides with capillary electrophoresis and detection using
an ABI sequence analyzer (Foster City, CA) at Michigan
State University’s Genomics Technology Support Facility, or
by manually sequencing with a Thermo Sequenase Radio-
labeled Terminator Cycle Sequencing kit (USB Corporation,
Cleveland, OH) and 33P-labeled dideoxynucleotide triphos-
phates according to the manufacturer’s protocol, followed
by 48 to 72 hours of exposure to Biomax MR Scientific Imag-
ing Film (Kodak, Rochester, NY).
Immunohistochemistry
Tissue sections of canine cutaneous MCTs were used for
the immunohistochemical evaluation of KIT protein locali-
zation, as previously described [39]. In brief, 5-mm sections of
formalin-fixed paraffin-embedded tissue were deparaffinized
in xylene, rehydrated in graded ethanol, and rinsed in dis-
tilled water. Endogenous peroxidase was neutralized with
3% hydrogen peroxide for 5 minutes. Antigen retrieval was
achieved by incubating slides in a citric buffer antigen re-
trieval solution (Dako, Carpinteria, CA) in a steamer (Black
and Decker, Towson, MD) for 20 minutes, and nonspecific
immunoglobulin binding was blocked by incubation of slides
for 10 minutes with a protein-blocking agent (Dako). Using
an autostainer, slides were incubated for 30 minutes with
a rabbit anti–human c-KIT antibody (Dako) at a dilution of
1:100. A streptavidin immunoperoxidase staining procedure
(Dako) was used for immunolabeling. The immunoreaction
was visualized with 3,3V-diaminobenzidine substrate (Dako).
Sections were counterstained with Mayer’s hematoxylin.
Positive and negative immunohistochemical controls were
included in each run. Known canine MCTs were used as
positive controls. Negative controls were canine MCTs that
were treated identically as routine sections, except that the
30-minute incubation with primary antibodies was replaced
with a 30-minute incubation with the buffer. KIT staining
patterns and protein localization for each MCT were charac-
terized as being perimembrane (KIT staining pattern I), focal
or stippled cytoplasmic (KIT staining pattern II), or diffuse
cytoplasmic protein localization (KIT staining pattern III), as
previously described [39] (Figure 3). The evaluation of KIT
Figure 1. LCM of neoplastic canine cutaneous MCTs (original magnification, 10). LCM was performed using archival formalin-fixed paraffin-embedded tissue
sections. DNA was extracted from captured cells, and PCR amplification was performed to identify c-KIT mutations. (A) Hematoxylin-stained section of MCT prior
to microdissection. (B) Section of MCT following microdissection. (C) Laser capture microdissected cells adhered to cap.
Figure 2. A 2% agarose gel of PCR-amplified c-KIT exon 11 and intron 11
from LCM-extracted DNA from canine MCTs. L: 100-bp ladder; M:
heterozygous for normal allele (191 bp) and mutant allele (250 bp), with an
upper band representing heterodimerization of normal and mutant alleles; N:
191-bp homozygous normal allele; NC: negative control (no template).
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protein localization was performed by a single investigator
(J.D.W.) to eliminate interobserver variability.
Tissue Microarray and Immunofluorescence
One-millimeter cores that were microscopically selected
to be representative of each tumor were taken from paraffin-
embedded MCT tissue blocks and were placed in a common
recipient paraffin block. MCTs included in the tissue array
were chosen based on the availability of tissues for transfer
to the recipient block. This resulted in 42 MCTsamples from
42 cases being represented on the tissue microarray. The
recipient block was subsequently heated at 37jC for ap-
proximately 1 hour to create a cohesive block. The Five-
Micron sections were cut and deparaffinized in xylene, and
subsequently dehydrated in graded alcohol with a final rinse
in distilled water. Twenty-minute steam retrieval in a citric
buffer solution (Dako) was used for antigen retrieval. Non-
specific antibody binding was performed with 5% donkey
serum with blocking buffer. Slides were incubated with pri-
mary rabbit anti–human c-KIT (Dako) antibodies at a dilution
of 1:100 overnight in a humidity chamber at 4jC. Sections
were then incubated with Cy-3– labeled secondary anti-
bodies, and nuclei were counterstained with 4V,6-diamidino-
2-phenylindole. Mean immunofluorescence was quantified
for each tumor sample using a Perkin Elmer Scan Array
(Perkin Elmer, Wellesley, MA).
Statistics
Univariable analyses. Before developing multivariable
models, each risk factor was evaluated for its association
with MCT outcomes. Univariable proportional hazards
models were developed for each risk factor for each outcome,
and the level of association was assessed through the risk
factors’ P value in the model. Risk factors with P V .20 were
considered for inclusion in the multivariable model, which
included the two variables c-KIT mutation status and KIT
staining pattern.
Multivariable logistic regression models. Logistic regres-
sion models were developed for the occurrence of out-
comes associated with MCTs, including recurrence of local
MCTs, recurrence of distant MCTs, and death associated
with MCTs. In addition to risk factors of interest, animal
signalment (age, sex, and weight) were included in the
multivariable model to account for their effects on model
outcome. Results were reported as odds ratio (OR): OR < 1
means that the likelihood of the occurrence of an event is
reduced, whereas OR > 1 indicates that the likelihood of an
event is increased.OR=1 indicates that the risk factor neither
increases or decreases the likelihood of the outcome.
Multivariable survival analysis models. This study used the
Cox proportional hazards models (SAS PROC PHREG)
(SAS Version 9.13; SAS Institute, Inc., Cary, NC) for survival
analysis, using survival times (time-to-event) as the model
outcome, and produced point estimates of the hazard ratio
(HR; risk ratio) for risk factors in the model. Proportional
hazards regression models were developed for the survival
analysis of different outcomes associated with MCTs. These
outcomes were days to recurrence of local MCTs, days to
recurrence of distant MCTs, and days to death resulting
from MCT. In addition to risk factors of interest, animal sig-
nalment (age, sex, and weight) was included in the multi-
variable model to account for their effects on model outcome.
The effects of risk factors on days to events were reported
as HRs. Comparable to OR, HR < 1 indicates that the risk
factor increases time to outcome, whereas HR > 1 indicates
that the risk factor decreases time to outcome.
Associations between c-KIT mutation status and KIT
staining patterns were tested using Mantel-Hanzel chi-
square analysis. Associations between c-KITmutation status
and mean immunofluorescence, and between KIT staining
patterns and mean immunofluorescence were tested using
Wilcoxon rank sum tests.
Results
Study Population
Sixty canine cutaneous MCTs from 60 dogs that met the
inclusion criteria were included in this study. The age of
these dogs ranged from 2 to 14 years, with a mean age of
7.84 years. Thirty-six dogs were females and 24 dogs were
males. A total of 19 different breeds was represented by the
study population. There were 13 mixed-breed dogs, 12 Lab-
rador retrievers, 10 boxers, 6 golden retrievers, 3 pugs,
Figure 3. Sections of canine cutaneous MCTs (skin) stained with anti-KIT antibodies and counterstained with hematoxylin (original magnification, 100, oil)
representing three patterns of KIT localization identified in neoplastic canine mast cells. (A) KIT staining pattern I, consisting of perimembrane protein localization.
(B) KIT staining pattern II, consisting of focal to stippled cytoplasmic staining. (C) KIT staining pattern III, consisting of diffuse cytoplasmic staining.
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2 bassett hounds, 2 springer spaniels, and 12 other breeds
represented by single dogs. According to the Patnaik histo-
logic grading system for canine MCTs [48], 8 MCTs were
grade 1, 45 MCTs were grade 2, and 7 MCTs were grade 3.
c-KIT Mutations in Canine MCTs
DNA fragments representing exon 11 of the c-KIT proto-
oncogene were amplified and visualized for each tumor.
c-KIT mutations were identified in 9 of 60 MCTs (15%). Mu-
tations in cases 1 to 8 were similar to previously described
ITD c-KIT mutations [30–33,52–54]. All of these ITD muta-
tions were in-frame mutations that ranged from 45 to 60 bp
in size. In cases 5, 6, 7, and 8, duplications extended by one,
two, three, and four nucleotides into intron 11, respectively.
The mutation in case 9 was located entirely in intron 11. This
mutation was tentatively identified as a duplication based
on its banding pattern on agarose gel electrophoresis, but,
when sequenced, it was found to consist of a 24-nucleotide
poly-T insertion followed by a 15-nucleotide duplication of
the sequence preceding the poly-T insertion. Additionally, a
G-to-A transition was found in the duplicated sequence
that preceded the poly-T insert. Four of the MCTs in which
mutations were identified were histologic grade 2 and five
were grade 3 (Table 1).
According to multivariable analysis, patients with MCTs
containing ITD c-KIT mutations had significantly decreased
survival times [P = .0068, HR = 6.23 (1.66–23.4)] and an
increased incidence of mortality due to MCT-related disease
[P = .0011, OR = 15 (2.95–76.31)] (Figure 4). Additionally,
patients with MCTs containing ITD c-KIT mutations were
also significantly associated with an increased incidence
of recurrence at the original tumor site [P = .0255, OR = 5.4
(1.23–23.75)] and at sites outside of the original tumor mar-
gins [P = .0016, OR = 6.13 (1.99–18.92)] and with a de-
creased disease-free interval both at the site of the original
tumor [P = .0157, HR = 5.78 (1.40–23.99)] and at sites out-
side of the tumormargin [P = .0012, HR= 6.14 (2.06–18.37)].
KIT Protein Localization and c-KIT Mutations
KIT protein localization was examined in each MCT using
immunohistochemical staining with anti-KIT antibodies.
Twenty-five of the 60 MCTs examined had KIT staining pat-
tern I, which is characterized by perimembrane KIT protein
localization, as seen in non-neoplastic (inflammatory) mast
cells. Twenty-four of 60 MCTs in this study had KIT staining
pattern II, which is characterized by stippled to focal cyto-
plasmic KIT localization, often with a decrease in perimem-
brane protein localization; the remaining 11 MCTs had KIT
staining pattern III, which is characterized by diffuse cyto-
plasmic KIT localization. Seven of nine MCTs (77.8%) with
ITD c-KIT mutations also had aberrant KIT protein localiza-
tion (KIT staining pattern II or III). Two of the MCTs with ITD
c-KIT mutations had KIT staining pattern I, three cases had
KITstaining pattern II, and four cases had KITstaining pattern
III. A significant trend was identified between the presence
of ITD c-KIT mutations and an increased cytoplasmic locali-
zation of KIT (P = .046) (Figure 5), as evidenced by higher KIT
staining patterns.
KIT Protein Expression
The tissue microarray representing 42 of 60 samples was
used to quantify KIT immunofluorescence. Relationships be-
tween immunofluorescence, and c-KIT mutations and KIT
Table 1. Mutation and Case Description for Cases with ITD c-KIT Mutations.
Case
Number
Duplication
Size
Duplication
Location
Histologic
Grade*
KIT Staining
Patterny
Local
Recurrence
(months)
Distant
Recurrence
(months)
MCT-Related
Death
(months)
Time to
Last Follow-Up
(If Alive) (months)
1 45 Exon 11 3 3 None None 0.5 N/A
2 45 Exon 11 2 2 None None None 29.1
3 45 Exon 11 3 3 None 0.5 0.5 N/A
4 45 Exon 11 2 2 0.5 0.5 0.5 N/A
5 60 Exon 11/intron 11 3 2 1 1 1 N/A
6 54 Exon 11/intron 11 3 3 2 2 3 N/A
7 60 Exon 11/intron 11 3 3 None 0.6 0.6 N/A
8 57 Exon 11/intron 11 2 1 None None None 7.3z
9 15 Intron 11§ 2 1 None None None 20.4
*Histologic grading was performed based on the Patnaik histologic grading system for canine cutaneous MCTs [48].
yKIT staining patterns were classified as described by Webster et al. [39].
zDog 8 died at 7.3 months due to causes unrelated to mast cell disease.
§Mutation in dog 9 consisted of a 24-bp poly-T insert with a 15-bp duplication, which was located entirely in intron 11. An additional A-to-G transition was also
identified in the duplicated sequence preceding the poly-T insert.
Figure 4. Kaplan-Meier survival curve: relative frequency of survival versus
time in months for canine cutaneous MCT patients with and without identified
c-KIT mutations. The presence of duplication mutation in the c-KIT proto-
oncogene was significantly associated with a decreased survival duration
[P = .0068, HR = 6.23 (1.66–23.40)].
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protein localization were investigated. No significant relation-
ships were identified (data not shown).
Discussion
The goal of this study was to look at the c-KIT proto-
oncogene and its product KIT at both the gene and protein
levels to better define the role this gene plays in the patho-
genesis of canine cutaneous MCTs. This is the first study
to demonstrate a significant association between c-KIT ITD
mutations, and an increased rate of recurrent disease and
mortality in dogs with canine cutaneous MCTs. Additionally,
this is the first study to identify a significant relationship be-
tween the presence of ITD c-KIT mutations and the aberrant
localization of KIT in canine MCTs. These data document
the importance of the c-KIT proto-oncogene in the tumori-
genesis of canine cutaneous MCTs and clearly identify the
c-KIT proto-oncogene as a potential target for the treatment
of canine MCTs.
The c-KIT proto-oncogene was first implicated in the
progression of canine cutaneous MCTs when activating
mutations were identified in the juxtamembrane domain of
c-KIT [31,32]. Following the identification of c-KIT mutations
in canine MCTs, work by our laboratory has shown that the
presence of c-KIT mutations is significantly associated with
higher histologic grade MCTs [33]. The results of this paper
further demonstrate the association of c-KIT mutations with
higher histologic grade MCTs in dogs. All of the MCTs with
c-KIT mutations identified in this study were of histologic
grades 2 and 3, whereas no grade 1 MCTs were found to
have c-KIT mutations. In this paper, we have further defined
the significance of ITD c-KIT mutations in canine MCTs by
showing that c-KIT ITDmutations are significantly associated
with an increased incidence of MCT-related death and with
an increased occurrence of MCTs at the original or distant
cutaneous or extracutaneous locations.
The prognostic value and biologic significance of molecu-
lar markers can be confounded by variations in the treatment
protocols used in a given study population. To overcome this
source of bias, only cases that were treated with surgical
excision alone (i.e., no chemotherapy or radiation therapy)
were included in this study. This is the only study that has
looked at the significance of c-KIT mutations in a population
of dogs treated with a single therapeutic protocol.
In this study, ITD c-KIT mutations were found in 15% of
the MCTs that were examined. The incidence of ITD c-KIT
mutations varied from 9% to 33% in the two previous studies,
which consisted of randomly selected and referral high-
grade tumors, respectively [33,53]. The predominance of
intermediate- and high-grade tumors in the latter study [53]
is likely to account for the high incidence of c-KIT mutations
in their study population. In the current study, cases were
randomly selected and represented the entire spectrum of
canine cutaneous MCTs [47,48,51]. Based on the results of
this study and previous studies, the true incidence of ITD
c-KIT is likely to be between 9% and 15% in all MCTs. How-
ever, these mutations may occur in as many as 50% of high-
grade canine MCTs [33,53].
Previously, our laboratory has shown that increased
cytoplasmic KIT protein localization in neoplastic mast cells
is associated with both a decreased disease-free survival
and an overall survival of dogs with cutaneous MCTs [39]. In
this study, we identified a significant association between
the presence of ITD c-KIT mutations and changes in KIT
localization in canine cutaneous MCTs. Seven of nine MCTs
with c-KIT mutations had aberrant KIT protein localization.
Although the significance of this relationship is not currently
clear, this may suggest that ITD c-KIT mutations may be
responsible for aberrant KIT localization in a subset of ca-
nine MCTs. Two cases with c-KIT mutations did not have
aberrant KIT localization and remain as outliers to this hy-
pothesis. However, the mutation in one of these MCTs was
located within intron 11 only, and therefore could be spliced
out during mRNA processing and may not be biologically
significant (case 9). It is also important to note that the dog
with the intronic c-KIT mutation (case 9) was still alive with
no report of local or distant recurrence at 20 months post-
surgery. Furthermore, significant statistical relationships
Figure 5. Correlation between ITD c-KITmutations and KIT protein localization in canine MCTs. A significant association was found between the presence of c-KIT
mutations and the cellular localization of KIT in canine MCTs (P = .046). Seven of nine (77.8%) MCTs with ITD c-KIT mutations had aberrant KIT localization in
neoplastic MCTs.
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between ITD c-KIT mutations and both the incidence of (P =
.0052) and time until MCT-related deaths (P = .0267) are
preserved when this mutation is not considered as a biolog-
ically significant mutation. A potential explanation for the
absence of cytoplasmic KIT localization in the other MCT
that had an ITD c-KIT mutation may be that this tumor only
recently acquired the mutation, and the changes in KIT
localization may not have occurred yet at the time of surgical
excision. However, ITD c-KIT mutations and changes in KIT
localization may represent separate events that occur inde-
pendent of one another in the progression of canine cutane-
ous MCTs. This hypothesis is supported by the fact that
28 MCTs included in this study had aberrant KIT localization
without the presence of ITD c-KITmutations. However, these
data could also indicate that, in addition to a direct causal
relationship between the ITD mutations and aberrant KIT
localization, other factors may be responsible for aberrant
KIT localization in canine cutaneous MCTs without ITD c-KIT
mutations. The primers that were used in this study do not
allow for the detection of the previously reported deletions
in canine MCTs because the forward primer is located in
the region of c-KIT that has been reported to be deleted in
a small subset of canine MCTs [32,33]. Therefore, although
rare, other c-KIT mutations, such as deletions in the juxta-
membrane domain, may be responsible for the aberrant
protein localization in those cases in which we did not identify
ITD c-KITmutations. In summary, the correlation between ITD
c-KIT mutations and aberrant KIT localization leads to many
interesting questions regarding the functional significance of
this relationship and the overall functional significance of
aberrantly localized KIT when ITD c-KIT mutations are not
present. Current work in our laboratory is focused on the
further characterization of aberrantly localized KIT and on
functional studies to better elucidate the relationship between
ITD c-KIT mutations and the aberrant localization of KIT.
No significant relationship was found in this study between
the presence of ITD c-KIT mutations or the aberrant locali-
zation of KITand the level of KIT protein expression as mea-
sured by mean immunofluorescence in a tissue microarray.
These results suggest that constitutive activation of KIT due
to ITD mutations or changes in signaling pathways through
aberrant KIT localization may be more important in the
pathogenesis of canine MCTs than overexpression of KIT
and subsequent increases in receptor sensitivity to its li-
gand. To clarify these observations, these results need to
be verified using additional techniques to quantify KIT protein
levels in canine MCTs. Additionally, further studies need to
be conducted to elucidate the functional significance of
aberrantly localized KIT and the effects it has on signaling in
neoplastic mast cells.
Spontaneous neoplastic diseases are commonly seen in
dogs [43,45] and, in many cases, share morphologic, clinical,
and molecular characteristics similar to those of human
neoplastic diseases. Therefore, these tumors are an excel-
lent in vivo model of spontaneous neoplasia that may be
utilized to better understand the roles of various genes and
proteins in the progression of neoplastic diseases, and to
serve as model systems for testing the safety and efficacy of
novel therapeutic agents [57,58]. Canine cutaneous MCTs
are one of the most common neoplasms in dogs and, unlike
human mastocytomas, often have an aggressive behavior
that can result in death. Due to the high incidence of canine
MCTs and the central role that c-KIT plays in MCT tumori-
genesis, canine MCTs can serve as an excellent in vivo
model for studying its role in the progression of this and
other human and animal neoplastic diseases. We propose
canine MCTs as a spontaneous in vivo model for clinical
trials aimed at determining the safety and efficacy of novel
targeted chemotherapeutic agents involving c-KIT signal-
ing pathways.
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